» Articles » PMID: 21933973

Targeting Axl and Mer Kinases in Cancer

Overview
Journal Mol Cancer Ther
Date 2011 Sep 22
PMID 21933973
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Receptor tyrosine kinases (RTK) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play an important role in signal transduction in both normal and malignant cells. The mammalian TAM RTK family includes 3 closely related members: Tyro-3, Axl, and Mer. Overexpression or ectopic expression of the TAM receptors has been detected in a wide array of human cancers. Growth arrest-specific gene 6 has been identified as the major ligand for these TAM RTKs, and its binding to the receptors has been shown to promote proliferation and survival of cancer cells in vitro. Abnormal expression and activation of Axl or Mer can provide a survival advantage for certain cancer cells. Inhibition of Axl and Mer may enhance the sensitivity of cancer cells to cytotoxic agents and would potentially be a therapeutic strategy to target cancer cells. This review elucidates the role of Axl and Mer in normal cellular function and their role in oncogenesis. In addition, we review the potential to inhibit these RTKs for the development of therapeutic targets in treatment of cancer.

Citing Articles

Navigating TAM receptor dynamics in tumour immunotherapy.

Yang J, Chen G, Wang R, Song C, Yi H Cancer Immunol Immunother. 2025; 74(5):146.

PMID: 40088262 DOI: 10.1007/s00262-024-03879-z.


Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?.

Malikova I, Worth A, Aliyeva D, Khassenova M, Kriajevska M, Tulchinsky E Cell Death Dis. 2025; 16(1):155.

PMID: 40044635 PMC: 11883011. DOI: 10.1038/s41419-025-07480-9.


AXL signaling in cancer: from molecular insights to targeted therapies.

Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L Signal Transduct Target Ther. 2025; 10(1):37.

PMID: 39924521 PMC: 11808115. DOI: 10.1038/s41392-024-02121-7.


Efferocytosis: The Janus-Faced Gatekeeper of Aging and Tumor Fate.

Liu Z, Li Y, Ren Y, Chen J, Weng S, Zhou Z Aging Cell. 2025; 24(2):e14467.

PMID: 39748782 PMC: 11822654. DOI: 10.1111/acel.14467.


From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

Crossman B, Harmon R, Kostecki K, McDaniel N, Iida M, Corday L J Clin Med. 2024; 13(20).

PMID: 39457986 PMC: 11508784. DOI: 10.3390/jcm13206036.